

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROFIT WARNING

This announcement is made by Tianda Pharmaceuticals Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that based on the preliminary assessments on the Group’s unaudited consolidated management accounts for the current interim period cover the six-month period from 1 January 2024 to 30 June 2024 (the “**Current Interim Period**”), it is expected that the Group’s revenue for the Current Interim Period will decrease by more than 48% as compared to the six-month period from 1 January 2023 to 30 June 2023 (the “**Previous Interim Period**”), and it is expected that the Group’s loss attributable to owners of the parent for the Current Interim Period will increase to a loss of not less than HK\$27 million as compared to that of HK\$4.1 million in the Previous Interim Period. The reasons are mainly due to (1) the substantial decline in the demand for the Group’s pediatric drug, Tuoen®Ibuprofen, after the aftershocks of the pandemic subsided and the demand for the drug returned to normal; and (2) during the renewal of the bidding of the centralized procurement of the Group’s cardio-cerebrovascular drug, Tuoping®Valsartan capsules in Jiangsu Province of China, due to the adoption of the strategy of lower pricing by competing bidders, the sales volume of “Tuoping” was affected during the Current Interim Period.

The Group is finalising the consolidated interim results of the Group for the Current Interim Period. Hence, the information disclosed in this announcement only represents a preliminary assessment by the Board and the management of the Group based on the information currently available to the Board. This preliminary assessment is not based on any financial figures and/or information which have been audited, verified or reviewed by the Company’s auditor or audit committee. As such, the results for the Current Interim Period may be different from what is disclosed in this announcement.

The Board expects that the announcement of the interim results of the Group will be published on 28 August 2024 in compliance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 22 August 2024

As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. ZHONG Tao and Mr. FENG Quanming; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.